back to news

Marinomed Biotech AG announces result of conversion of convertible bonds


Corporate news transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is responsible for the content of this announcement.

Vienna – 18 February 2019. Marinomed Biotech AG announces that by the end of the conversion period on 14 February 2019 (16:00 CET), conversion notices for nominal value of EUR 6.98 million of the 4% Bonds 2017-2021 with Conditional Conversion Rights, ISIN AT0000A1WD52 (equivalent to approximately 99.7% of the outstanding volume of the convertible bonds), have been submitted for conversion into new shares of Marinomed Biotech AG. Following the issuance of the new shares, the total number of shares will increase by 170,772 new shares to 1,430,772 (corresponding to an increase in share capital of around 13.6%). The free float rises to around 39% (assuming full exercise of the greenshoe option). The issuance and start of trading of the new shares from the convertible bonds are scheduled for 20 February 2019.

Andreas Grassauer, CEO of Marinomed:”The successful IPO and the high conversion rate confirm that we provide an attractive story for investors with our innovative platforms. We welcome all new shareholders and look forward to working with them to further advance our success story.”

About Marinomed Biotech AG Marinomed Biotech AG is a Vienna based biopharmaceutical company focusing on the development of innovative products derived from patent protected technology platforms to treat respiratory and ophthalmic conditions. The Carragelose® platform comprises innovative patent protected products targeting viral infections of the respiratory tract. Carragelose® is used in nasal sprays, throat sprays and lozenges, which are sold in more than 30 countries around the world in collaboration with international partners. The Marinosolv® technology platform increases the efficacy of hardly soluble compounds for the treatment of sensitive tissues such as the eyes and nose. Further information is available at

Disclaimer This announcement does not constitute an offer to purchase securities or solicitation of an offer to purchase securities in the United States of America, Germany, Austria or other jurisdictions. This press release contains forward- looking statements, which are based on current views, expectations and projections of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described in, or expressed or implied by, such statements. The current views, expectations and projections of the management of Marinomed Biotech AG may be identified by the context of such statements or words such as “anticipate,” “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and “target”. Forward-looking statements speak only as of the date they are made and Marinomed Biotech AG does not assume any obligation to update, review or revise any forward-looking statement contained in this press release whether as a result of new information, future developments or otherwise.

Further inquiry note: Eva Prieschl-Grassauer PhD Chief Scientific Officer, Marinomed Veterinärplatz 1, 1210 Vienna, Austria Tel.: +43 (0)1 250 77 4460 E-mail:

Roland Mayrl
Managing Partner
Metrum Communications
Prinz-Eugen-Straße 80/16,
1040 Vienna, Austria
Tel.: +43 (0) 1 504 69 87 331